Ten years with empagliflozin – change of paradigm in the treatment of type 2 diabetes mellitus

Czech version

Authors: O. Ga Bobelová
Authors‘ workplace: DIOLI s. r. o., Košice
Published in: Forum Diab 2025; 14(2): 138-141
Category: News

Overview

Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, represents a major milestone in the treatment of type 2 diabetes mellitus (T2D). Over ten years of clinical practice, it has been established as a medication with proven cardioprotective and nephroprotective effects that go far beyond glycemic control. Robust clinical evidence from randomized trials such as EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY, as well as real-world studies, has confirmed its benefit in reducing cardiovascular and renal morbidity and mortality.

Keywords:

type 2 diabetes mellitus (T2D) – empagliflozin – cardioprotective effects – nephroprotective effects – sodium-glucose co-transporter 2 (SGLT2) inhibitor

Sources

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and the EASD. Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.

Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <https://doi/10.1056/NEJMoa1504720>.

Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

Packer M, Anker SD, Butler J et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

Anker SD, Butler J, Filippatos G et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/ 10.1056/NEJMoa2204233>.

American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes –⁠ 2024. Diabetes Care 2023; 47(Suppl 1). Dostupné z DOI: <https://doi.org/10.2337/dc24-SREV>.

McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023; 44(37): 3627–3639. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehad195>.

KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4, Suppl): S117–S314.

Lacka J, Martinka E, Uličiansky V et al. Štandardné postupy: Komplexný manažment diabetikov 2. typu –⁠ 2024. Diab Obez 2024; 24(Supplement): 1–58.

Martinka E, Mokáň M, Rašlová K et al. Interdisciplinárne štandardy diagnostiky a liečby diabetes mellitus, jeho komplikácií a najvýznamnejších sprievodných ochorení –⁠ 2021. Forum Diab 2021; 10(Suppl 2): S4-S279.

Patorno E, Pawar A, Franklin JM et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) Study. Circulation 2019; 139(25): 2822–2830. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039177>.

McGuire DK, Zinman B, Inzucchi SE et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol 2020; 8(12): 949–959. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(20)30344–2>.

Melzer-Cohen C, Schechter M, Rozenberg A et al. Long-term, Real-World kidney outcomes with SGLT2i versus DPP4i in type 2 diabetes without cardiovascular or kidney disease. Clin J Am Soc Nephrol 2023; 18(9): 1153–1162. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.0000000000000218>.

Fernández-Fernández B, Sarafidis P, Soler MJ et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 2023; 16(8): 1187–1198. Dostupné z DOI: <http://dx.doi.org/10.1093/ckj/sfad082>.

Claggett B, Lachin JM, Hantel S et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation 2018; 138(15): 1599–1601. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033810>.

Monteiro P, Bergenstal RM, Toural E et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age Ageing 2019; 48(6): 859–866. Dostupné z DOI: <http://dx.doi.org/10.1093/ageing/afz096>.

Jardiance. Súhrn údajov o prípravku. Informácie dostupné z WWW: <https://www.sukl.csk>.

Zoznam Indikačných obmedzení. MZ SR. Dostupné z WWW: <https://www.health.gov.sk/Clanok?lieky202503>.